🔬 Call for Abstracts – PSOGI 2025 🔬 Peritoneal Surface Oncology Group International (PSOGI)
https://t.co/FQ3JqVFmg0
From SMALL Beginnings to a GLOBAL FORCE 💪
@PSOGI_EC invites researchers, clinicians, and professionals in the field to submit their abstracts for PSOGI 2025. This is a unique opportunity to showcase your latest research and contribute to the advancement of peritoneal surface malignancies.
📌 Submission Guidelines:
https://t.co/wwuOmo4iyv
📅 Deadline: June 1st at 23:59 (CET).
Join a global community of experts, share groundbreaking findings, and be part of the conversation shaping the future of peritoneal oncology.
🔗 Submit your abstract today!
TOPICS:
✓ Peritoneal metastases from colorectal cancer
✓ Peritoneal metastases from gastric cancer
✓ Peritoneal metastases of ovarian cancer
✓ Pseudomyxoma peritonei
✓ Peritoneal mesotelioma
✓ Diagnosis and staging of peritoneal surface malignancies
✓ Intraperitoneal treatment for peritoneal surface malignancies
✓ Patient-centered care in peritoneal surface malignancies
✓ Basic science related to peritoneal surface malignancies
✓ Artificial Intelligence and big data approaches in peritoneal surface malignancies
✓ Educational on peritoneal surface malignancies
✓ Perioperative care
hashtag
#PSOGI2025
#PeritonealOncology
#CallForAbstracts
#MedicalResearch
@DrSGlezMoreno@alarjosan@cascalescirugia@operarelcancer@indepso@ISSPP1@SPeritoneum@NewsJellybelly@prof_paolo61616@SWexner@DeliaCortesGuir@docswapnil01@MufaddalKazi@ESSOnews@ejsotweets
🔬 Call for Abstracts – PSOGI 2025 🔬 Peritoneal Surface Oncology Group International (PSOGI)
https://t.co/FQ3JqVFmg0
From SMALL Beginnings to a GLOBAL FORCE 💪
@PSOGI_EC invites researchers, clinicians, and professionals in the field to submit their abstracts for PSOGI 2025. This is a unique opportunity to showcase your latest research and contribute to the advancement of peritoneal surface malignancies.
📌 Submission Guidelines:
https://t.co/wwuOmo4iyv
📅 Deadline: June 1st at 23:59 (CET).
Join a global community of experts, share groundbreaking findings, and be part of the conversation shaping the future of peritoneal oncology.
🔗 Submit your abstract today!
TOPICS:
✓ Peritoneal metastases from colorectal cancer
✓ Peritoneal metastases from gastric cancer
✓ Peritoneal metastases of ovarian cancer
✓ Pseudomyxoma peritonei
✓ Peritoneal mesotelioma
✓ Diagnosis and staging of peritoneal surface malignancies
✓ Intraperitoneal treatment for peritoneal surface malignancies
✓ Patient-centered care in peritoneal surface malignancies
✓ Basic science related to peritoneal surface malignancies
✓ Artificial Intelligence and big data approaches in peritoneal surface malignancies
✓ Educational on peritoneal surface malignancies
✓ Perioperative care
hashtag
#PSOGI2025
#PeritonealOncology
#CallForAbstracts
#MedicalResearch
@DrSGlezMoreno@alarjosan@cascalescirugia@operarelcancer@indepso@ISSPP1@SPeritoneum@NewsJellybelly@prof_paolo61616@SWexner@DeliaCortesGuir@docswapnil01@MufaddalKazi@ESSOnews@ejsotweets
It is my pleasure to invite all surgical , gynecology and medical oncology doctor to join us onsite or virtually for the biggest meeting in the Middle East @PSOGI_EC , speakers from all continents will join to discuss the latest advance in peritoneal cancer in Jeddah
It is my pleasure to invite all surgical , gynecology and medical oncology doctor to join us onsite or virtually for the biggest meeting in the Middle East @PSOGI_EC , speakers from all continents will join to discuss the latest advance in peritoneal cancer in Jeddah
Post
See new posts
Conversation
📷Indian society of peritoneal surface malignancy@IspsmHipec@IspsmHipec@somusp9@ECPSOGI@TDellingerMD@ISSPP1@oliviawriting@DeliaCortesGuir@DrSGlezMoreno@RobellaManuela@oliviawriting@ISSPP1@MartinHbner3@MarcRaymond
Post
See new posts
Conversation
📷Indian society of peritoneal surface malignancy@IspsmHipec@IspsmHipec@somusp9@ECPSOGI@TDellingerMD@ISSPP1@oliviawriting@DeliaCortesGuir@DrSGlezMoreno@RobellaManuela@oliviawriting@ISSPP1@MartinHbner3@MarcRaymond
In conclusion, CHIPOR provides robust evidence that
HIPEC improves overall survival in patients undergoing
complete cytoreductive surgery for platinum-sensitive
recurrent ovarian cancer. Progression-free survival was
also improved, particularly peritoneal progression-free
survival. Toxicity was increased with the use of HIPEC
and this treatment should be administered in specialist
centres with experience of preventing and managing
toxicities and with access to prophylactic thiosulfate.
Nevertheless, there was no detectable detrimental effect
on quality of life with HIPEC and no increase in pain in
the immediate postoperative period. Therefore, when
treating patients with late first relapse of high-grade
serous or high-grade endometrioid ovarian cancer
amenable to complete cytoreductive surgery, platinum-
based HIPEC should be considered to extend
overall survival.
@IspsmHipec@PSOGI_EC@ISSPP1@glehenolivier
In conclusion, CHIPOR provides robust evidence that
HIPEC improves overall survival in patients undergoing
complete cytoreductive surgery for platinum-sensitive
recurrent ovarian cancer. Progression-free survival was
also improved, particularly peritoneal progression-free
survival. Toxicity was increased with the use of HIPEC
and this treatment should be administered in specialist
centres with experience of preventing and managing
toxicities and with access to prophylactic thiosulfate.
Nevertheless, there was no detectable detrimental effect
on quality of life with HIPEC and no increase in pain in
the immediate postoperative period. Therefore, when
treating patients with late first relapse of high-grade
serous or high-grade endometrioid ovarian cancer
amenable to complete cytoreductive surgery, platinum-
based HIPEC should be considered to extend
overall survival.
@IspsmHipec@PSOGI_EC@ISSPP1@glehenolivier
📅 One week to go! Don’t miss the ESSO-SICO Webinar on Ovarian Peritoneal Metastasis. 🔬 Join on 31 Oct to learn about #HIPEC, #CytoreductiveSurgery, & #PIPAC. Register now for FREE! 🔗https://t.co/0udFZdw6wx
Info: https://t.co/r1V9XoRVIz
#ESSOWebinar#SurgicalOncology#MedEd
📅 One week to go! Don’t miss the ESSO-SICO Webinar on Ovarian Peritoneal Metastasis. 🔬 Join on 31 Oct to learn about #HIPEC, #CytoreductiveSurgery, & #PIPAC. Register now for FREE! 🔗https://t.co/0udFZdw6wx
Info: https://t.co/r1V9XoRVIz
#ESSOWebinar#SurgicalOncology#MedEd
🚨 Get ready for the ESSO-SICO Webinar on the treatment of ovarian peritoneal metastasis!
🗓️ 31 Oct, 5pm CET
Register for FREE today! https://t.co/JufsnBnhTC
#ESSOWebinar#OvarianCancer#HIPEC#SurgicalOncology
🚨 Get ready for the ESSO-SICO Webinar on the treatment of ovarian peritoneal metastasis!
🗓️ 31 Oct, 5pm CET
Register for FREE today! https://t.co/JufsnBnhTC
#ESSOWebinar#OvarianCancer#HIPEC#SurgicalOncology
Only 3 days left until the early rates for registration are over for the 1st joint ISSPP - PSOGI congress on #PSM (peritoneum). Please hurry on our website
https://t.co/BfGb20TmnM
Hyperthermic intraperitoneal chemotherapy in colorectal cancer
➡️https://t.co/MLFKFNFTdb
This is a large multicentric global study combining a number of large national peritoneal surface oncology databases from three continents (39 centres) for evaluating the use and choice of hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal metastasized colorectal cancer undergoing cytoreductive surgery. It is the largest study in the field of peritoneal surface oncology for colorectal cancer with crude survival analysis in over 2000 patients and propensity score matched survival analysis in over 1300 patients. This study found that oxaliplatin-based HIPEC resulted in superior overall and recurrence-free survival compared to mitomycin C-based HIPEC—a finding which persisted after propensity score matching. However, high-dose mitomycin C protocols resulted in improved survival, and a dose–response relationship between low-dose and high-dose HIPEC treatment regardless of protocol drug used was further discovered.
👏👏👏@OMaxFisher, Chris Brown, Jesus Esquivel, Stein G Larsen, Winston Liauw, Nayef A Alzahrani, David L Morris, Vahan Kepenekian, Isabelle Sourrouille, Frédéric Dumont, Jean-Jacques Tuech, Cécilia Ceribelli, Béranger Doussot, Olivia Sgarbura, Mohammed Alhosni, Francois Quenet, Olivier Glehen, @CashinPtr, Peritoneal Surface Oncology Group International (PSOGI), Nordic Peritoneal Oncology Group (NPOG), American Society for Peritoneal Surface Malignancy (ASPSM) and BIG-RENAPE Groups
#SoMe4Surgery #MedTwitter #SurgEd #Surgery
@me4_so@for_surgery@for_surgeons@modern_surgeon@surggpt@BJSAcademy@BJSurgery@young_bjs@juliomayol@JJEarnshaw @OUPMedicine #colorectalsurgery #colorectalcancer @FightCRC #StepUp4CRC #HIPEC
Delphi Study on PIPAC Published in the EJSO :IMPACT study group , congratulation all and happy and proud to contribute to this with colleagues , Prof. Wouter Willaert Prof. Wim Ceelen Dr. Niki Rashidian Dr. Eduard Callebaut Dr. Martin Hübner Dr. Olivia Sgarbura Dr. Francesca Tozzi
@PSOGI_EC@IspsmHipec@ISSPP1
Delphi Study on PIPAC Published in the EJSO :IMPACT study group , congratulation all and happy and proud to contribute to this with colleagues , Prof. Wouter Willaert Prof. Wim Ceelen Dr. Niki Rashidian Dr. Eduard Callebaut Dr. Martin Hübner Dr. Olivia Sgarbura Dr. Francesca Tozzi
@PSOGI_EC@IspsmHipec@ISSPP1